featured
Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Clin. Cancer Res 2024 Oct 15;[EPub Ahead of Print], E Hamilton, MD Galsky, S Ochsenreither, G Del Conte, M Martín, MJ de Miguel, EY Yu, A Williams, M Gion, AR Tan, L Agrawal, A Rutten, JP Machiels, S Cresta, PR Debruyne, A Hennequin, V Moreno, A Minchom, F Valdes-Albini, D Petrylak, L Li, Z Tsuchihashi, F Suto, FC Cheng, M Kandil, D Barrios, S HurvitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.